COMMUNIQUÉS West-GlobeNewswire

Levicept Presents New Data Suggesting a Novel Neurotrophin-3 Inhibitor, LEVI-04, May Modify Disease and Improve Symptoms in Osteoarthritis
27/10/2025
Clinical and Pharmacology Data Presented at ACR Convergence 2025 In a Phase II trial, LEVI-04 demonstrated a significant, dose-dependent reduction in bone marrow lesions (BML) compared with placebo in patients with [...]
NHS-licensed healthcare platform Evaro partners with period tracking app Clue in UK-first integration
27/10/2025
Partnership bridges the gap between period tracking and contraception access as nearly half of UK women face barriers to contraception care LONDON, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Evaro, the NHS-licensed embedded [...]
Rakovina Therapeutics Showcases Potent AI-Developed ATR Inhibitors with CNS Penetrance at AACR-NCI-EORTC International Conference
27/10/2025
VANCOUVER, British Columbia, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV)(FSE: 7JO0) is pleased to announce the successful presentation of new data at the AACR- [...]
Citryll Presents Positive Data from Phase I Study of CIT-013 in Rheumatoid Arthritis at ACR Convergence 2025
27/10/2025
CITRYLL PRESENTS POSITIVE DATA FROM PHASE I STUDY OF CIT-013 IN RHEUMATOID ARTHRITIS AT ACR CONVERGENCE 2025 Phase I trial data in rheumatoid arthritis patients demonstrates favorable safety, encouraging clinical [...]
World's First Multi-Omics LLM, Promising to Decode the Language of Human Biology Showcasing in Global Health Exhibition, Riyadh
27/10/2025
PanOmiQ’s foundational model trained on multi-Omics data breakthrough FPGA-powered deployment addresses data sovereignty challenge, ultrafast AI-driven multi-omics analysis on premises, redefining speed and accuracy in [...]
Genenta Announces Pricing of $15.0 Million Registered Direct Offering of American Depositary Shares
27/10/2025
MILAN and NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a pioneer in immuno-oncology, today announced that it has entered into a securities purchase agreement with institutional investors [...]
Health Canada Grants Authorization for “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease
27/10/2025
In Canada, lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment or mild dementia due to Alzheimer’s disease (early AD) who are apolipoprotein E ε4 (ApoE ε4*) [...]
Vivani Medical, Inc. Announces Pricing of Common Stock Offering
27/10/2025
ALAMEDA, Calif., Oct. 26, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today [...]
MapLight Therapeutics Announces Pricing of Initial Public Offering
26/10/2025
SAN FRANCISCO and BOSTON, Oct. 26, 2025 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous [...]
New Global Coalition Launches to Address the Hidden Threat of RSV in Adults
26/10/2025
VIENNA, Austria, Oct. 26, 2025 (GLOBE NEWSWIRE) -- A new global coalition, the RSV Alliance, has been launched to raise awareness about the risks of respiratory syncytial virus (RSV) infections, with a focus on aging [...]
New Data at American College of Gastroenterology Annual Meeting Show TissueCypher® Provides Actionable Risk Insights that Influence Clinical Management and Prompt Risk-Aligned Intervention in Barrett’s Esophagus
26/10/2025
Research on TissueCypher by Horvath et al. honored with a Presidential Poster Award from the ACG Abstract Selection Committee, a distinction awarded to only 5-7% of abstracts for research deemed high quality, novel or [...]
Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline
26/10/2025
Ad hoc announcement pursuant to Art. 53 LR Transaction strengthens neuroscience franchise for Novartis with three late-stage programs that address genetic neuromuscular diseases Advances the Novartis xRNA strategy by [...]

Pages

Other news

Test 2

22/10/2026

Lorem ipsum

Test 1

22/10/2026

Lorem upsum